Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Exosome stem cell treatment for hair loss, which is expensive and reportedly effective, but its popularity has declined. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.

KX-826 is available on Amazon but not shipped to the Netherlands. The user seeks advice on obtaining it in Europe.

VDPHL01, an extended-release oral minoxidil tablet, showed promising results in improving hair coverage for 79 to 86% of men in a trial, with fewer side effects compared to standard doses. Many users prefer oral minoxidil over topical due to ease of use and fewer side effects, especially for those with pets.

The conversation discusses applying KX826 for hair loss without wasting it, with a suggestion to buzz the hair for easier application. The user considers using a 0.9% version after finding the 0.5% version insufficient.

Exosome therapy for hair loss is questioned, with microneedling and topical minoxidil/dutasteride being more supported treatments. Concerns are raised about testosterone therapy affecting hair loss, and the lack of standardization and approval for exosome products.

The user is considering starting Minoxidil and is looking for a topical solution to combine with it. They are confused about which product to prioritize among options like RU58841, Pyrilutamide, FinaTopic, and DutaTopic.

Minoxidil should be applied first, allowed to dry, then emu oil can be applied. Emu oil is recommended for daily use, but it may not need to be washed off daily.

Verteporfin updates for hair loss and its trials. Users also express interest in exosomes.

The user is using topical minoxidil and finasteride with good results and is considering adding stemoxydine 5% to their regimen. Another user suggests trying it if financially feasible, as results can vary.

OP used finasteride 1mg and 2.5mg oral minoxidil since late April, showing hair improvement despite some initial libido issues. Users discussed side effects, costs, and alternative treatments, with OP noting increased facial hair but no significant body hair growth.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The conversation discusses the use of KX826 for hair loss, with mixed opinions on its effectiveness. Some users are skeptical, mentioning no significant progress or regrowth, and others suggest it might be a scam or that data may be manipulated.

A 45-year-old user shared progress pictures after 4 months of using a topical gel with 2.5% finasteride and 5% minoxidil once daily. The second picture shows significant improvement in hair growth.

The user had been using Minoxidil and Dutasteride with micro-needling but experienced hair loss after switching Minoxidil brands. Their doctor prescribed oral Minoxidil and Tretinoin, but the pharmacist suggested isotretinoin might be a more cost-effective alternative.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

OP is considering switching from ketoconazole shampoo to piroctone olamine (PTO) due to scalp irritation. Users report mixed experiences, with some finding PTO less irritating and more soothing than ketoconazole.

The conversation is about finding an affordable source for KX 826 powder for hair loss treatment. One user mentions using it alongside dutasteride and minoxidil.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

A 29-year-old doctor in Australia shares his 10-year experience with finasteride and 1-year experience with oral minoxidil for hair maintenance, reporting no significant side effects and effective hair preservation. He also uses a nizoral shampoo and a compounded tablet containing finasteride, minoxidil, and a multivitamin.

Exosomes are not effective for long-term hair regrowth, with users reporting temporary improvements or no noticeable change. Effective treatments include Dutasteride, Finasteride, Minoxidil, and RU58841, with other options like CB-03-01 and Fluridil offering limited benefits.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Minoxidil can be effectively delivered through nanoemulsions containing eucalyptol or oleic acid, enhancing its diffusivity and targeting hair follicles. This contradicts the advice against mixing minoxidil with oils in topical formulations.

A user discusses using a mixed solution with minoxidil 2%, hydrocortisone butyrate, and estrone in the morning, and considering adding 5% minoxidil at night. They also use Restax softgel but avoid finasteride.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

A 20-year-old has been using finasteride and topical minoxidil for a year but is considering adding oral minoxidil, dutasteride, and biotin due to unsatisfactory results. Opinions vary, with some suggesting patience and others recommending different treatments, but caution is advised against using multiple oral drugs due to potential side effects.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

The user experienced good results with a topical blend of finasteride and minoxidil, along with dermarolling, after stopping oral finasteride due to side effects. However, they faced significant shedding when transitioning from oral to topical treatment.

OP saw significant hair growth after starting scalp exfoliation and using 5% topical minoxidil for 4.5 months, along with microneedling initially. Users discussed the benefits of exfoliation and inquired about experiences with finasteride and dutasteride.